Le Lézard
Classified in: Health, Science and technology, Business
Subject: OFR

Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering


ATLANTA, Dec. 22, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outside of the brain, announced today the pricing of its initial public offering of 1,800,000 shares of common stock at a public offering price of $10.00 per share, for gross proceeds of $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by Inhibikase. All of the shares are being offered by Inhibikase. In addition, Inhibikase has granted the underwriters a 45-day option to purchase up to an additional 270,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. 

The shares are expected to begin trading on the Nasdaq Capital Market on December 23, 2020 under the ticker symbol "IKT." The offering is expected to close on December 28, 2020, subject to the satisfaction of customary closing conditions. 

ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.

A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission (SEC) on December 22, 2020. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, from the offices of ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, or by email at prospectus@think-equity.com. These documents may also be obtained free of charge, when they are available, by visiting the SEC's website at www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

About Inhibikase (www.inhibikase.com)
Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's Disease and related disorders that arise inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.

Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements, including statements regarding the closing of the initial public offering and the proceeds of the initial public offering, are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase's filings with the SEC, including its registration statement on Form S-1, as amended (File No. 333-240036), including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:
Investor Relations:
Milton H. Werner, PhD
President & CEO, Inhibikase
678-392-3419
mhwerner@inhibikase.com

Media:
Mary Moynihan
M2Friend Biocommunications
802-951-9600
mary@m2friend.com

SOURCE Inhibikase Therapeutics


These press releases may also interest you

at 19:00
SK hynix Inc. (or "the Company", www.skhynix.com) announced that it has started mass-production of 18GB (gigabyte) LPDDR5 mobile DRAM, which offers the largest capacity in the industry. This product will be equipped in premium smartphones to support...

at 16:29
MeaTech 3D Ltd. ("MeaTech"), a technology company focused on developing and out-licensing its proprietary three-dimensional printing technology, biotechnology processes and customizable manufacturing processes to food processing and food retail...

at 16:25
BetaShares, a leading Australian ETF manager with more than $16 billion in assets under management, today announced that it has received a significant investment from TA Associates, a leading global growth private equity firm, to fuel a major...

at 15:05
Veeva Systems announced that LSK Global Pharma Services Co. Ltd, a leading Korean contract research organization (CRO), has adopted Veeva Vault eTMF, Veeva Vault CTMS, and Veeva SiteVault Free. With Veeva Vault Clinical applications, LSK Global PS...

at 01:00
UFC®, the world's premier mixed martial arts organization, today announced a new partnership with Stake.com, the world's largest cryptocurrency casino and sportsbook. Under the terms of the agreement, Stake.com will become UFC's first-ever "Official...

at 01:00
SYSTRAN, the leader in neural automated translation technology, announces it has signed a business partnership agreement with FAPCOTECH General Trading Company ("FAPCOTECH Integrated Business Solutions") for the representation of SYSTRAN's Products...



News published on 22 december 2020 at 18:25 and distributed by: